Skip to main content

HPS News from the American Thoracic Society meeting




I am finally rested up from my trip and have so much to share about our experience at the American Thoracic Society. A big shout out and thank you to everyone that helped out including: Candice and Crystal Sipe, Donna and Ashley Appell, Demetria Saffore, Kristen Brantner and Carrie Frew.

I’ll start with what everyone really wants to know – what happened with the drug trials being discussed for pulmonary fibrosis??? Grin!

The meeting was very exciting. I went to a class on diagnosing pulmonary fibrosis and the class just sort of fell apart into one big party. One of the docs told me, “I’ve been treating patients with pulmonary fibrosis for 30 years and for the first time I will have a real treatment to offer them.”

The results of the Pirfenidone trial (the second one ordered by the FDA) were encouraging. Everyone seems to think it will be approved with no trouble this time and that it will be on the market in a year. I’m hoping for sooner, but to be realistic, a year is probably about right if no other snags occur.

The company that makes the drug has announced an Early Access program for the drug, but it is only for patients with idiopathic pulmonary fibrosis, not HPS. At this time it does not include HPS. We are working on some strategic advocacy right now to try to make that happen, but I want to be very realistic. It could take some time if it is successful at all.

The good news is I do not think we will have any trouble at all finding doctors in the US to prescribe Pirfenidone off label to HPSers once it is on the market. The issue is going to be whether insurance is going to cover it.

The feedback we got on that issue was about 50/50.
Some thought it might be a problem, while others thought it would be no big deal. I think we’re going to have to wait on that issue until it is on the market, and act like we think of course we’re going to get it. Do nothing to red flag to anyone that it even might be an issue, and see what happens. One doc said to me that he didn’t think it would be an issue because there are so few HPSers that it wouldn’t be worth it to the insurers to fight about it. It’s expensive, but they’ll be paying for it for thousands of people with IPF, thus HPSers will be a drop in the bucket.

In the meantime, we need to build the case for HPS. We need those that were in the drug trials to go back to NIH for follow up. I can’t stress how important this is now.

There was a second drug trial for another drug called Nintedanib (BIBF1120) that reported phase III results that showed benefit. We do not have any history with HPS and this drug. I am not totally sure about the biochemistry, or what part of the disease pathway it hits etc. to know if it would be helpful to us. We’re asking our researchers now. Everyone seemed to think this drug would also be on the market in about a year, assuming that it also doesn’t run into any bumps like Pirfenidone did.

Lastly, they reported on a trial with NAC and this trial showed no benefit.

Let me be very clear. Neither one of these drugs is a cure. They might just slow things down a bit, and they might not work for everyone. It’s a first step in a journey that is ongoing.

We are working on the issue of access for HPSers. Right now I don’t want to say more than that because I don’t want to do anything to endanger a delicate process. Please know, however, that we are actively working on this. When and if the time comes, we will need everyone on deck ready, but I hope the process turns out to go smoother than that and major lobbying isn’t needed. Still, be ready if we send out the call!

Lastly, about that journey.

Dr. Zhou (he was one of the researchers we funded) presented some research at the meeting that had everyone buzzing, even the non HPS researchers. It’s all a little above my head, but he thinks he’s found a possible therapeutic target that would be HPS specific and directed therapy, rather than these drugs coming out now that are sort of more general in nature. Dr. Zhou even won an award for his research at the meeting! So, there are better things in the pipeline.

I know we all want them now. I get it as I need a therapy yesterday – but this was perhaps one of the most promising and exciting meetings we’ve had yet!
Labels:

Comments

Post a Comment

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for
1 comment
Read more

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.
Post a Comment
Read more

Help for one of our newest HPS friends

As many of you know, I have a google alert set up for all sorts of key terms like albinism, pulmonary fibrosis etc. The following was posted on the blog of a friend of Melanie's. Melanie is one of our newest members of the Hermansky-Pudlak Syndrome family. Unfortunately, like so many she didn't know she had HPS and the lung disease sort of snuck up on her. Melanie will be 26 years old next week. Perhaps some of us would like to contribute to the fund set up to help her and her family for her birthday. Here's the post: Melanie Hernandez, beloved sister and daughter to Pete, Monique, Cookie, and Bugie, has been diagnosed with Pulmonary Fibrosis, a lung disease occurring in people with Hermansky-Pudlak Syndrome, a very rare disease.Hermansky-Pudlak Syndrome (“HPS”) is a genetic metabolic disorder. It is characterized by: Albinism, Vision Impairment, Bleeding Disorder, Inflammatory Bowel Disease and Lung Disease – Pulmonary Fibrosis. With the family’s research and the recollect
Post a Comment
Read more